Introduction
Epilepsy is associated with an increased fracture risk two to six times that of the general population with about 40% of fractures directly related to seizures. 1 Antiepileptic drugs (AED) have negative effects on bone mineral density (BMD) and concentration (BMC) through a variety of mechanisms, the most significant thought to be an increased rate of bone turnover. 2 The AEDs most commonly associated with bone disease are inducers of the cytochrome P450 enzyme system, 3 but this is not the sole cause of AED-induced osteopathy. The non-enzyme inducing AEDs do not confer any protection over BMD.
Further, epilepsy may be associated with other factors that result in reduced BMD, such as immobility. We determined the prevalence of osteoporosis and the factors associated with reduced BMD in patients with chronic epilepsy within a longer-term care facility.
Methods
Bone densitometry was performed in 208 patients (145 male) with a median age of 45 years (range: 20-86 years). Distal radius BMD and BMC were measured by dual energy X-ray absorptiometry Seizure (2007) Summary Bone mineral density (BMD) and content (BMC) were measured in 208 institutionalised patients with refractory epilepsy. BMD was in the osteoporotic range in 43% of males and 21% of females. BMC was reduced only in male patients. Apart from age and gender, no other factor or specific AED was particularly associated with reduced BMD or BMC. This study indicates the magnitude of the problem of bone disease in refractory epilepsy, in particular affecting young and male patients with chronic epilepsy. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
(DXA). This forearm region is affected minimally by degenerative changes compared with the spine. 5 Calcium, 25(OH)-vitamin-D, parathyroid hormone (PTH) and AED levels were measured routinely. Previous and current AED therapy, fractures and wheelchair dependency were ascertained from the medical notes. Statistical analysis was carried out in SPSS 11.0. Unpaired T-tests and Mann-Whitney U-tests were used where appropriate. Multiple regression was used to determine significant contributing factors to absolute BMD and logistic regression to determine which covariates increased the odds of having BMD T-score in the osteoporotic rather than normal range.
Results
There was no difference in age, BMI and clinical parameters between genders ( Table 1 ). The population had a high fracture risk with 67% of patients having a history of fractures and 54% of patients having at least one fracture since admission.
AED treatment
Only one patient had started treatment with AEDs after reaching the age of peak skeletal bone mass. Four patients had only ever tried one AED, all others had tried at least two up to 17 AEDs (median number of AEDs tried: 7). The number of current regular AEDs ranged from 0 to 5 with a median of 2. Only two patients were currently not on AEDs. Thirty-nine patients were on monotherapy, and the remainder were on polytherapy with two AEDs (n = 79), three AEDs (65), four AEDs (16), or five AEDs (2) . Most of the patients (86%) had been treated with carbamazepine ( Table 2) .
BMD and BMC
According to the WHO definition, 65 patients (31%) were osteopaenic (À1.1 < T-score < À2.49) and 76 patients (37%) were osteoporotic (T < À2.5). The prevalence of osteoporosis was greater among men (43%) than women (21%). Age and gender corrected BMD Z-scores were significantly lower in patients than in the normal population (Z: À1.10; p 0.001) ( Table 3) . Men (BMD-Z: À1.42; p 0.001) were more affected than women (BMD-Z: À0.36; p = 0.004). Patients' BMC Z-scores were significantly lower than that of the normal population (Z: À1.01; p = 0.0001), but this was only significant for men (Z: À1.42; p = 0.0001), not for women (Z: À0.1; p = 0.43).
Prior to DXA scans, seven patients were treated with bisphosphonates. Four of those seven patients were osteoporotic, and three had normal T-scores. A further 12 patients were on vitamin-D/Ca supplementation. Of those 12 patients, 5 were osteoporotic, 3 osteopenic and 4 had normal T-scores. Excluding these patients from the analysis did not affect the results of the above comparisons.
Biochemistry
Biochemical data were comparable between genders, apart from PTH (females: 5.38 pmol/l versus males: 2.57 pmol/l; p = 0.04) Six patients (all female) had raised PTH (>8.5 pmol/l). Three patients had vitamin-D deficiency (25-OHD < 10 ng/ml) and 33 patients had vitamin-D insufficiency (10 ng/ml < 25-OHD < 20 ng/ml). There was neither significant correlation between vitamin-D levels and history of fractures, nor between BMD and vitamin-D or PTH levels.
Osteoporosis (T-score < 2.5) versus normal BMD
Patients with osteoporosis (n = 76; median age 55 years) were significantly older than patients with normal BMD (n = 67; 41 years; p 0.001). The osteoporotic group had significantly longer duration of epilepsy. There was no significant difference in BMI, age of epilepsy onset or AED history between osteoporotic and normal groups for either male or female. Wheelchair dependency did not relate to BMD or BMC. Although a higher proportion of osteoporotic patients had sustained one or more fractures compared with patients with normal BMD (56% c.f. 48%) this was not significant ( p = 0.33).
Using simple linear regression analysis adjusting for age and gender, there was a significant negative association between BMD with age of onset (B = À2.77 Â 10
À3
, S.E. = 0.001, p = 0.024, multiple correlation coefficient R = 0.47). There was no significant association between age of onset and BMC, and no association between either BMD or BMC and other variables.
Using logistic regression, being male was associated with a five-fold increase in odds of osteoporosis compared with females, and every year increased the odds of osteoporosis by 4%. No other variable was a significant contributor in this analysis.
AED treatment: osteoporosis versus normal BMD
Effect of enzyme inducers Only 11 patients had never been treated with known enzyme inducers, and their BMD-and BMC Z-scores were not different from the remainder. There was no difference between patients (n = 60) never treated with phenytoin, primidone or phenobarbitone, and patients (n = 148) exposed to any of these three AEDs. Univariate analysis of variance, correcting for age and sex, did not reveal any association between BMD and duration of various AEDs. Of the 39 patients on monotherapy, 25 were on carbamazepine or oxcarbazepine, 7 on phenytoin, 3 on lamotigine, 2 on valproate and 1 each on levetiracetam and topiramate. Analysis was limited by the small numbers of the individual therapies, but there was no significant difference between BMD Z-scores in patients on carbamazepine/oxcarbazepine monotherapy and phenytoin, or between carbamazepine/oxcarbazepine monotherapy and other monotherapy.
Effect of enzyme inhibitors
Treatment in the past or present with a known enzyme inhibitor was not associated with higher BMD-or BMC Z-scores.
Effect of new AEDs
Patients prescribed the ''new AEDs'' (e.g., lamotrigine, topiramate, oxcarbazepine, levetiracetam, gabapentin and tiagabine) were significantly younger than patients not on new AEDs (new AED: 43 years versus old AED: 55 years; p 0.001). BMDand BMC Z-scores were not different between patients who had been treated for more than 6 months with a new AED (n = 135) and those (n = 73) never treated with these AEDs.
Discussion
In our population of institutionalised patients with refractory epilepsy, BMD was significantly reduced compared to the normal population. In contrast to the normal population, male patients had twice the risk of osteoporosis than females. The group with osteoporosis was older, as expected. Every year was associated with a 4% increase in risk of osteoporosis. Except for gender and age, no other contributing factors could be isolated. No specific AED, nor type of AED such as enzyme inducer or inhibitor, old or new, significantly increased the risk of osteoporosis. There was no difference between those treated with phenytoin, phenobarbitone and primidone, and those never treated with these drugs. The newer AEDs were prescribed to a significantly younger population and for a shorter duration, and thus, their long-term effects cannot be compared with the older agents.
Our results are contrary to other studies. 6 The enzyme inducing AEDs most commonly associated with bone disease were not found to be associated with lower BMD, BMC or vitamin-D levels. A potentially bone sparing effect of acetazolamide was reported in women, 7 suggesting that newer, less potent carbonic anhydrase inhibitors (e.g., topiramate or zonisamide) might have a similar effect. Our findings for topiramate or acetazolamide are not more favourable than for the other AEDs and a more recent study associated acetazolamide with increased bone loss. 6 Our cross-sectional audit does not allow to separate the effects of duration of epilepsy and longterm AED treatment. The number of AEDs tried over the years correlated with the duration of epilepsy and age of the patients. The negative association between age of epilepsy onset and BMD but not BMC is difficult to explain. It is possible that patients who started AEDs around puberty had the worst affected bone growth, and thus lower BMD but not BMC, as this is mineralization rather than growth.
Our data analysis is complicated by many factors contributing to osteoporosis, such as institutionalisation and immobility. Patients had been in residential care on average for 17 years and 20% were wheelchair-dependent, which generally increases the incidence of reduced BMD. 2 Serial biochemistry measurements rather than single snapshots would have been more useful in the analysis of their relationship with bone density. BMD and BMC take longer to change and reflect a couple of years of bone turnover. Other factors known to be associated with osteoporosis were not surveyed, such as concurrent medication other than AED, and smoking history.
The peripheral scanner used has many advantages, such as portability, cost and simplicity of use, but it is a screening, not a diagnostic tool with forearm measurements correlating only moderately with hip and poorly with spine BMD. 8 However vertebral fractures have been associated with decreased BMD at the distal radius, and distal forearm BMD has enabled the prediction of future fractures of the hip in postmenopausal women, although the predictive power is not as strong as BMD measurements at the hip itself. 9 In postmenopausal women the pattern of bone loss is more global whereas wheelchair use reduces predominantly hip BMD, and this might explain why we did not find a correlation between immobility and forearm BMD. Nevertheless, our findings are consistent with a recent study showing reduced BMD in the femoral neck in epileptic patients irrespective of whether they had been treated with enzyme inducers or noninducers. 10 
Conclusion
Our findings support the hypotheses that AED treatment may have negative effects on BMD particularly aggravated in male patients and by other factors related to institutionalisation. A further audit is required to assess the benefits of regular screening and prophylactic supplementation with vitamin-D and calcium.
